Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer
The programmed death‐1/programmed death‐ligand 1 (PD‐L1) pathway is a negative feedback pathway that suppresses the activity of T cells. Previous studies reported that high PD‐L1 expression on tumor cells (TC) was associated with poor survival in patients with colorectal cancer; however, the prognos...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2017-05, Vol.108 (5), p.853-858 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 858 |
|---|---|
| container_issue | 5 |
| container_start_page | 853 |
| container_title | Cancer science |
| container_volume | 108 |
| creator | Koganemaru, Shigehiro Inoshita, Naoko Miura, Yuji Miyama, Yu Fukui, Yudai Ozaki, Yukinori Tomizawa, Kenji Hanaoka, Yutaka Toda, Shigeo Suyama, Koichi Tanabe, Yuko Moriyama, Jin Fujii, Takeshi Matoba, Shuichiro Kuroyanagi, Hiroya Takano, Toshimi |
| description | The programmed death‐1/programmed death‐ligand 1 (PD‐L1) pathway is a negative feedback pathway that suppresses the activity of T cells. Previous studies reported that high PD‐L1 expression on tumor cells (TC) was associated with poor survival in patients with colorectal cancer; however, the prognostic evaluation of these studies was limited because they included patients at various disease stages. The purpose of the present study was to evaluate the relationship between PD‐L1 status in the immune microenvironment and the clinicopathological features of stage III colorectal cancer. Two hundred and thirty‐five patients were included in the analysis. PD‐L1 expression on TC and tumor‐infiltrating mononuclear cells (TIMC) was evaluated by immunohistochemistry. The median follow‐up of thisi study was 52.9 months. A total of 8.1% of stage III colorectal cancer showed high PD‐L1 expression on TC and 15.3% showed high PD‐L1 expression on TIMC. Patients with high PD‐L1 expression on TC had significantly shorter disease‐free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21–4.62; P = 0.012). In addition, patients with high PD‐L1 expression on TIMC were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16–0.98; P = 0.046). These findings suggest that PD‐L1 expression status may be a new predictor of recurrence for stage III colorectal cancer patients and highlight the necessity of evaluating PD‐L1 expression on TC and TIMC separately in the tumor microenvironment.
High PD‐L1 expression on tumor cells was significantly associated with a poor prognosis, whereas high PD‐L1 expression on tumor‐infiltrating mononuclear cells positively affected the prognosis of patients with stage III colorectal cancer. |
| doi_str_mv | 10.1111/cas.13229 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5448596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2289413758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4679-d12a11fe4e21c00707dc5419be86dcbd5c1ce9cbf2f4fcb33c91cbcf3f17ac763</originalsourceid><addsrcrecordid>eNp1kc9qFTEUhwdRbK0ufAEJuKmLaXOSzGSyEcrFPxcKCuo6ZM6cmZsyd3JNZlq78xF8Rp_EtLcWFczmhOTj43f4FcVz4CeQzym6dAJSCPOgOASpTKk5rx_e3nVpuBQHxZOULjiXtTLqcXEgGlFrIdRhMXyMYZhCmj2ySzcuxELPdvktuu2WOtaRmzc_v_8Y_eCmjgGjb7tIKfkwMT-xnZs9TXNiV37esDS7gdh6vWYYxhAJZzcydBNSfFo86t2Y6NndPCq-vH3zefW-PP_wbr06Oy9R1dqUHQgH0JMiAci55rrDSoFpqak7bLsKAclg24te9dhKiQawxV72oB3qWh4Vr_fe3dLm_JjDRTfaXfRbF69tcN7-_TP5jR3Cpa2UaipzIzi-E8TwdaE0261PSOPoJgpLstDoCpQEEBl9-Q96EZY45fWsEI1RIHXVZOrVnsIYUorU34cBbm_qs7k-e1tfZl_8mf6e_N1XBk73wJUf6fr_Jrs6-7RX_gIykaed</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289413758</pqid></control><display><type>article</type><title>Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>PubMed Central</source><creator>Koganemaru, Shigehiro ; Inoshita, Naoko ; Miura, Yuji ; Miyama, Yu ; Fukui, Yudai ; Ozaki, Yukinori ; Tomizawa, Kenji ; Hanaoka, Yutaka ; Toda, Shigeo ; Suyama, Koichi ; Tanabe, Yuko ; Moriyama, Jin ; Fujii, Takeshi ; Matoba, Shuichiro ; Kuroyanagi, Hiroya ; Takano, Toshimi</creator><creatorcontrib>Koganemaru, Shigehiro ; Inoshita, Naoko ; Miura, Yuji ; Miyama, Yu ; Fukui, Yudai ; Ozaki, Yukinori ; Tomizawa, Kenji ; Hanaoka, Yutaka ; Toda, Shigeo ; Suyama, Koichi ; Tanabe, Yuko ; Moriyama, Jin ; Fujii, Takeshi ; Matoba, Shuichiro ; Kuroyanagi, Hiroya ; Takano, Toshimi</creatorcontrib><description>The programmed death‐1/programmed death‐ligand 1 (PD‐L1) pathway is a negative feedback pathway that suppresses the activity of T cells. Previous studies reported that high PD‐L1 expression on tumor cells (TC) was associated with poor survival in patients with colorectal cancer; however, the prognostic evaluation of these studies was limited because they included patients at various disease stages. The purpose of the present study was to evaluate the relationship between PD‐L1 status in the immune microenvironment and the clinicopathological features of stage III colorectal cancer. Two hundred and thirty‐five patients were included in the analysis. PD‐L1 expression on TC and tumor‐infiltrating mononuclear cells (TIMC) was evaluated by immunohistochemistry. The median follow‐up of thisi study was 52.9 months. A total of 8.1% of stage III colorectal cancer showed high PD‐L1 expression on TC and 15.3% showed high PD‐L1 expression on TIMC. Patients with high PD‐L1 expression on TC had significantly shorter disease‐free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21–4.62; P = 0.012). In addition, patients with high PD‐L1 expression on TIMC were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16–0.98; P = 0.046). These findings suggest that PD‐L1 expression status may be a new predictor of recurrence for stage III colorectal cancer patients and highlight the necessity of evaluating PD‐L1 expression on TC and TIMC separately in the tumor microenvironment.
High PD‐L1 expression on tumor cells was significantly associated with a poor prognosis, whereas high PD‐L1 expression on tumor‐infiltrating mononuclear cells positively affected the prognosis of patients with stage III colorectal cancer.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.13229</identifier><identifier>PMID: 28267224</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Apoptosis ; B7-H1 Antigen - metabolism ; Cancer ; Cancer therapies ; CD8‐positive T‐lymphocytes ; Chemotherapy ; Cloning ; colonic neoplasms ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - metabolism ; Colorectal Neoplasms - pathology ; Death ; Disease-Free Survival ; Humans ; immune microenvironment ; Immunohistochemistry ; Immunohistochemistry - methods ; Leukocytes (mononuclear) ; Ligands ; Lymphocytes ; Lymphocytes T ; Lymphocytes, Tumor-Infiltrating - metabolism ; Lymphocytes, Tumor-Infiltrating - pathology ; Medical prognosis ; Original ; Patients ; PD-1 protein ; PD-L1 protein ; Prognosis ; Radiation therapy ; Research funding ; Studies ; Surgery ; Survival analysis ; Tumor cells ; tumor infiltrating mononuclear cells ; Tumor Microenvironment - physiology</subject><ispartof>Cancer science, 2017-05, Vol.108 (5), p.853-858</ispartof><rights>2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4679-d12a11fe4e21c00707dc5419be86dcbd5c1ce9cbf2f4fcb33c91cbcf3f17ac763</citedby><cites>FETCH-LOGICAL-c4679-d12a11fe4e21c00707dc5419be86dcbd5c1ce9cbf2f4fcb33c91cbcf3f17ac763</cites><orcidid>0000-0003-1323-4896 ; 0000-0001-9279-5952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448596/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448596/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11543,27903,27904,45553,45554,46030,46454,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28267224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koganemaru, Shigehiro</creatorcontrib><creatorcontrib>Inoshita, Naoko</creatorcontrib><creatorcontrib>Miura, Yuji</creatorcontrib><creatorcontrib>Miyama, Yu</creatorcontrib><creatorcontrib>Fukui, Yudai</creatorcontrib><creatorcontrib>Ozaki, Yukinori</creatorcontrib><creatorcontrib>Tomizawa, Kenji</creatorcontrib><creatorcontrib>Hanaoka, Yutaka</creatorcontrib><creatorcontrib>Toda, Shigeo</creatorcontrib><creatorcontrib>Suyama, Koichi</creatorcontrib><creatorcontrib>Tanabe, Yuko</creatorcontrib><creatorcontrib>Moriyama, Jin</creatorcontrib><creatorcontrib>Fujii, Takeshi</creatorcontrib><creatorcontrib>Matoba, Shuichiro</creatorcontrib><creatorcontrib>Kuroyanagi, Hiroya</creatorcontrib><creatorcontrib>Takano, Toshimi</creatorcontrib><title>Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>The programmed death‐1/programmed death‐ligand 1 (PD‐L1) pathway is a negative feedback pathway that suppresses the activity of T cells. Previous studies reported that high PD‐L1 expression on tumor cells (TC) was associated with poor survival in patients with colorectal cancer; however, the prognostic evaluation of these studies was limited because they included patients at various disease stages. The purpose of the present study was to evaluate the relationship between PD‐L1 status in the immune microenvironment and the clinicopathological features of stage III colorectal cancer. Two hundred and thirty‐five patients were included in the analysis. PD‐L1 expression on TC and tumor‐infiltrating mononuclear cells (TIMC) was evaluated by immunohistochemistry. The median follow‐up of thisi study was 52.9 months. A total of 8.1% of stage III colorectal cancer showed high PD‐L1 expression on TC and 15.3% showed high PD‐L1 expression on TIMC. Patients with high PD‐L1 expression on TC had significantly shorter disease‐free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21–4.62; P = 0.012). In addition, patients with high PD‐L1 expression on TIMC were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16–0.98; P = 0.046). These findings suggest that PD‐L1 expression status may be a new predictor of recurrence for stage III colorectal cancer patients and highlight the necessity of evaluating PD‐L1 expression on TC and TIMC separately in the tumor microenvironment.
High PD‐L1 expression on tumor cells was significantly associated with a poor prognosis, whereas high PD‐L1 expression on tumor‐infiltrating mononuclear cells positively affected the prognosis of patients with stage III colorectal cancer.</description><subject>Apoptosis</subject><subject>B7-H1 Antigen - metabolism</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>CD8‐positive T‐lymphocytes</subject><subject>Chemotherapy</subject><subject>Cloning</subject><subject>colonic neoplasms</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Death</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>immune microenvironment</subject><subject>Immunohistochemistry</subject><subject>Immunohistochemistry - methods</subject><subject>Leukocytes (mononuclear)</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphocytes, Tumor-Infiltrating - metabolism</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Medical prognosis</subject><subject>Original</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Research funding</subject><subject>Studies</subject><subject>Surgery</subject><subject>Survival analysis</subject><subject>Tumor cells</subject><subject>tumor infiltrating mononuclear cells</subject><subject>Tumor Microenvironment - physiology</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc9qFTEUhwdRbK0ufAEJuKmLaXOSzGSyEcrFPxcKCuo6ZM6cmZsyd3JNZlq78xF8Rp_EtLcWFczmhOTj43f4FcVz4CeQzym6dAJSCPOgOASpTKk5rx_e3nVpuBQHxZOULjiXtTLqcXEgGlFrIdRhMXyMYZhCmj2ySzcuxELPdvktuu2WOtaRmzc_v_8Y_eCmjgGjb7tIKfkwMT-xnZs9TXNiV37esDS7gdh6vWYYxhAJZzcydBNSfFo86t2Y6NndPCq-vH3zefW-PP_wbr06Oy9R1dqUHQgH0JMiAci55rrDSoFpqak7bLsKAclg24te9dhKiQawxV72oB3qWh4Vr_fe3dLm_JjDRTfaXfRbF69tcN7-_TP5jR3Cpa2UaipzIzi-E8TwdaE0261PSOPoJgpLstDoCpQEEBl9-Q96EZY45fWsEI1RIHXVZOrVnsIYUorU34cBbm_qs7k-e1tfZl_8mf6e_N1XBk73wJUf6fr_Jrs6-7RX_gIykaed</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Koganemaru, Shigehiro</creator><creator>Inoshita, Naoko</creator><creator>Miura, Yuji</creator><creator>Miyama, Yu</creator><creator>Fukui, Yudai</creator><creator>Ozaki, Yukinori</creator><creator>Tomizawa, Kenji</creator><creator>Hanaoka, Yutaka</creator><creator>Toda, Shigeo</creator><creator>Suyama, Koichi</creator><creator>Tanabe, Yuko</creator><creator>Moriyama, Jin</creator><creator>Fujii, Takeshi</creator><creator>Matoba, Shuichiro</creator><creator>Kuroyanagi, Hiroya</creator><creator>Takano, Toshimi</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1323-4896</orcidid><orcidid>https://orcid.org/0000-0001-9279-5952</orcidid></search><sort><creationdate>201705</creationdate><title>Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer</title><author>Koganemaru, Shigehiro ; Inoshita, Naoko ; Miura, Yuji ; Miyama, Yu ; Fukui, Yudai ; Ozaki, Yukinori ; Tomizawa, Kenji ; Hanaoka, Yutaka ; Toda, Shigeo ; Suyama, Koichi ; Tanabe, Yuko ; Moriyama, Jin ; Fujii, Takeshi ; Matoba, Shuichiro ; Kuroyanagi, Hiroya ; Takano, Toshimi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4679-d12a11fe4e21c00707dc5419be86dcbd5c1ce9cbf2f4fcb33c91cbcf3f17ac763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Apoptosis</topic><topic>B7-H1 Antigen - metabolism</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>CD8‐positive T‐lymphocytes</topic><topic>Chemotherapy</topic><topic>Cloning</topic><topic>colonic neoplasms</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Death</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>immune microenvironment</topic><topic>Immunohistochemistry</topic><topic>Immunohistochemistry - methods</topic><topic>Leukocytes (mononuclear)</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphocytes, Tumor-Infiltrating - metabolism</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Medical prognosis</topic><topic>Original</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Research funding</topic><topic>Studies</topic><topic>Surgery</topic><topic>Survival analysis</topic><topic>Tumor cells</topic><topic>tumor infiltrating mononuclear cells</topic><topic>Tumor Microenvironment - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koganemaru, Shigehiro</creatorcontrib><creatorcontrib>Inoshita, Naoko</creatorcontrib><creatorcontrib>Miura, Yuji</creatorcontrib><creatorcontrib>Miyama, Yu</creatorcontrib><creatorcontrib>Fukui, Yudai</creatorcontrib><creatorcontrib>Ozaki, Yukinori</creatorcontrib><creatorcontrib>Tomizawa, Kenji</creatorcontrib><creatorcontrib>Hanaoka, Yutaka</creatorcontrib><creatorcontrib>Toda, Shigeo</creatorcontrib><creatorcontrib>Suyama, Koichi</creatorcontrib><creatorcontrib>Tanabe, Yuko</creatorcontrib><creatorcontrib>Moriyama, Jin</creatorcontrib><creatorcontrib>Fujii, Takeshi</creatorcontrib><creatorcontrib>Matoba, Shuichiro</creatorcontrib><creatorcontrib>Kuroyanagi, Hiroya</creatorcontrib><creatorcontrib>Takano, Toshimi</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koganemaru, Shigehiro</au><au>Inoshita, Naoko</au><au>Miura, Yuji</au><au>Miyama, Yu</au><au>Fukui, Yudai</au><au>Ozaki, Yukinori</au><au>Tomizawa, Kenji</au><au>Hanaoka, Yutaka</au><au>Toda, Shigeo</au><au>Suyama, Koichi</au><au>Tanabe, Yuko</au><au>Moriyama, Jin</au><au>Fujii, Takeshi</au><au>Matoba, Shuichiro</au><au>Kuroyanagi, Hiroya</au><au>Takano, Toshimi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2017-05</date><risdate>2017</risdate><volume>108</volume><issue>5</issue><spage>853</spage><epage>858</epage><pages>853-858</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>The programmed death‐1/programmed death‐ligand 1 (PD‐L1) pathway is a negative feedback pathway that suppresses the activity of T cells. Previous studies reported that high PD‐L1 expression on tumor cells (TC) was associated with poor survival in patients with colorectal cancer; however, the prognostic evaluation of these studies was limited because they included patients at various disease stages. The purpose of the present study was to evaluate the relationship between PD‐L1 status in the immune microenvironment and the clinicopathological features of stage III colorectal cancer. Two hundred and thirty‐five patients were included in the analysis. PD‐L1 expression on TC and tumor‐infiltrating mononuclear cells (TIMC) was evaluated by immunohistochemistry. The median follow‐up of thisi study was 52.9 months. A total of 8.1% of stage III colorectal cancer showed high PD‐L1 expression on TC and 15.3% showed high PD‐L1 expression on TIMC. Patients with high PD‐L1 expression on TC had significantly shorter disease‐free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21–4.62; P = 0.012). In addition, patients with high PD‐L1 expression on TIMC were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16–0.98; P = 0.046). These findings suggest that PD‐L1 expression status may be a new predictor of recurrence for stage III colorectal cancer patients and highlight the necessity of evaluating PD‐L1 expression on TC and TIMC separately in the tumor microenvironment.
High PD‐L1 expression on tumor cells was significantly associated with a poor prognosis, whereas high PD‐L1 expression on tumor‐infiltrating mononuclear cells positively affected the prognosis of patients with stage III colorectal cancer.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>28267224</pmid><doi>10.1111/cas.13229</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1323-4896</orcidid><orcidid>https://orcid.org/0000-0001-9279-5952</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2017-05, Vol.108 (5), p.853-858 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5448596 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; PubMed Central |
| subjects | Apoptosis B7-H1 Antigen - metabolism Cancer Cancer therapies CD8‐positive T‐lymphocytes Chemotherapy Cloning colonic neoplasms Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Death Disease-Free Survival Humans immune microenvironment Immunohistochemistry Immunohistochemistry - methods Leukocytes (mononuclear) Ligands Lymphocytes Lymphocytes T Lymphocytes, Tumor-Infiltrating - metabolism Lymphocytes, Tumor-Infiltrating - pathology Medical prognosis Original Patients PD-1 protein PD-L1 protein Prognosis Radiation therapy Research funding Studies Surgery Survival analysis Tumor cells tumor infiltrating mononuclear cells Tumor Microenvironment - physiology |
| title | Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A43%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20programmed%20death%E2%80%90ligand%201%20expression%20in%20patients%20with%20stage%20III%20colorectal%20cancer&rft.jtitle=Cancer%20science&rft.au=Koganemaru,%20Shigehiro&rft.date=2017-05&rft.volume=108&rft.issue=5&rft.spage=853&rft.epage=858&rft.pages=853-858&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.13229&rft_dat=%3Cproquest_pubme%3E2289413758%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289413758&rft_id=info:pmid/28267224&rfr_iscdi=true |